A
Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
XETRA:APPH
Price:
11.25
EUR
-1.32%
Market Closed
Market Cap:
95.6m
EUR
Apontis Pharma AG
Cash Interest Paid
|
Apontis Pharma AG
Cash Interest Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash Interest Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Cash Interest Paid
€100
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Cash Interest Paid
$1.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Cash Interest Paid
€2B
|
CAGR 3-Years
17%
|
CAGR 5-Years
5%
|
CAGR 10-Years
14%
|
|
|
Merck KGaA
XETRA:MRK
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Cash Interest Paid
€53.8m
|
CAGR 3-Years
89%
|
CAGR 5-Years
52%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Cash Interest Paid
€4m
|
CAGR 3-Years
189%
|
CAGR 5-Years
267%
|
CAGR 10-Years
N/A
|
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
APPH
Intrinsic Value
16.07
EUR
Undervaluation 30%
A
See Also
What is Apontis Pharma AG's Cash Interest Paid?
Cash Interest Paid
100
EUR
100
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Cash Interest Paid amounts to 100 EUR.
You don't have any saved screeners yet